1. Home
  2. CDLR vs IVA Comparison

CDLR vs IVA Comparison

Compare CDLR & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

N/A

Current Price

$24.77

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$6.63

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDLR
IVA
Founded
2008
2011
Country
Denmark
France
Employees
N/A
84
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
CDLR
IVA
Price
$24.77
$6.63
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$16.20
AVG Volume (30 Days)
78.1K
345.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$142.95
N/A
Revenue Next Year
$70.44
N/A
P/E Ratio
$7.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$2.70
52 Week High
$26.79
$7.98

Technical Indicators

Market Signals
Indicator
CDLR
IVA
Relative Strength Index (RSI) 50.21 59.24
Support Level $19.00 $5.79
Resistance Level $25.21 $7.17
Average True Range (ATR) 0.63 0.30
MACD -0.32 -0.02
Stochastic Oscillator 31.91 63.29

Price Performance

Historical Comparison
CDLR
IVA

About CDLR Cadeler AS

Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: